Cancer Medicines Forum (CMF) – a way forward for treatment optimisation

5 April 2024
Virtual meeting / EMA, Amsterdam

The European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) are co-chairing the Cancer Medicines Forum (CMF). The CMF was created to address the challenges with regards to treatment optimisation taking into consideration the International Conference of Harmonisation E9(R1).

The main objectives of the CMF are to:

- Serve as a direct and official communication channel with the academic community in oncology.
- To identify key research questions and best methodological approach to improve the clinical use of cancer medicines.
- To discuss the uptake of academic work in the wider context of regulatory decision-making in oncology.

The CMF will be reporting its observations and preliminary solutions to address treatment optimisation at a hybrid workshop and discuss the proposed way forward.

Cancer Medicines Forum (CMF)– a way forward for treatment optimisation

Chaired by Denis Lacombe (EORTC) and Francesco Pignatti (EMA)

12:30 Joining and technical checks

13:00 Welcome and opening speech

Presentation
Emer Cooke, Executive Director, EMA

Welcome (video)
Frank Vandenbroucke, Deputy Prime Minister and Minister of Health and Social Affairs

13:15 Session 1: Setting principles and rationale for treatment optimisation

Cancer Medicines Forum: rationale and achievements **20'**
Denis Lacombe, Chief Executive Officer, EORTC

Examples of drug development and optimisation questions/trials **30'**
Iphigenie Korakis, Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France
Bertrand Tombal, department of Surgery and Urology UCL, Brussels BE
Martin Kaiser, European Haematology Association

How could EU policies benefit of the work of the CMF? **20'**
Richard Sullivan, Kings college London, UK

Cancer Medicines Forum treatment optimisation framework **15'**
Caroline Voltz-Girolt, advanced therapy and haematological diseases office, EMA

14:40 Q&A

14:50 Session 2: Developing a new regulatory dimension for treatment optimisation

Cancer Drug Development as a Public Health Issue **15'**
Chris Booth, Queen's University Cancer Research Institute, Canada

The global Challenges of Post-market Optimisation Research **15'**
Daniel Goldstein, Tel-Aviv University

FDA Oncology centre of excellence: project PRAGMATICA **15'**
Donna Rivera, Associate Director of Pharmacoepidemiology, Real World Data and Real World Evidence, FDA

How does treatment optimisation apply to other fields of medicine? **20'**
Guy Brusselle, Ghent University Hospital, Belgium

15:55 Q&A

16:00 Coffee break

16:30 Panel Discussion

Regulator's perspective: *Pierre Demolis, ANSM, EMA*
HTA's perspective: *Beate Wieseler: Head of Department Drug Assessment, IQWIG*
Patient's perspective*: Ana Amariutei, European Patient Advocacy Institute*
Clinician's perspective*: Rosa Giuliani, HealthCare Professional Working Party*
Industry's perspective: *Michael Zaiac, Daiichi Sankyo*
Head of Medicines Agency's perspective: *Momir Radulovic, Agency for Medicinal Products and Medical Devices of the Republic of Slovenia*
Payer's perspective: *Ackbar Ketwaru, the Ministry of Health, Welfare and Sport, The Netherlands*
WHO Perspective: *Raffaella Casolino, World Health Organization*

18:00 Closing remarks

Wrap up: recommendations to the CMF and EU Policy makers Wrap up **15'**
Denis Lacombe (EORTC) and Francesco Pignatti (EMA)